Hims & Hers Health, Inc. (HIMS)
Last updated: 2026-11-19 07:45:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Hims & Hers Health, Inc. (HIMS) operates in the SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE sector and is listed on NYSE. The stock is currently priced at $17.06, with a market capitalization of $4.11B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.74 to $40.99. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$4.11B | |
$17.89 | |
$18.18 | |
$17.03 | |
$17.55 | |
8.47M | |
11.90M | |
-- | |
$40.99 | |
$13.74 | |
-- | |
2026-09-30 |
Hims & Hers Health, Inc. (HIMS) Latest Closing Stock Price
Hims & Hers Health, Inc. (HIMS) last closed at $17.06 as of 2026-11-19 00:59:31, down 1.99% ($0.35) from the previous close of $17.55.
During the latest regular trading session, HIMS traded between $17.03 and $18.18, with a volume of 8.47M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Hims & Hers Health, Inc. (HIMS) 7-Day Stock Price Change
Over the past seven days, Hims & Hers Health, Inc. (HIMS) moved from $19.13 to $17.06, representing a decline of 10.84% ($2.07).
The stock traded between $17.02 and $22.47 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 20.16 million shares, up versus the previous seven-day period, indicating higher trading activity.
HIMS 52-Week Price Position
Position in Range: 12.2%
HIMS is currently trading at $17.06, placing it 12.2% of the way from its 52-week low of $13.74 to its 52-week high of $40.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Hims & Hers Health, Inc. (HIMS)?
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2.7 million subscribers, is available in all 50 states and certain international markets including the UK, Germany, and Australia. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health, Inc. Information
| Industry | SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE |
| Employees | 2,442 |
| CEO | Andrew Dudum |
| Founded | 2017 |
| Exchange | NYSE |
| Company Website |
HIMS News
Latest news related to Hims & Hers Health, Inc. and HIMS stock.
- Read Full Article
- Read Full Article
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?
Hims & Hers Health stock plummeted following earnings results that revealed strong 49% revenue growth but concerning profitability issues. The company posted a $66.1 million operating loss compared to an $11.8 million profit a year ago, with gross margins deteriorating from 74% to 57%. The analyst recommends avoiding the stock until the company demonstrates sustainable profitable growth.
- Read Full Article
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
Hims & Hers stock crashed 17% after issuing weak Q4 guidance, with revenue projections falling short of analyst expectations at $875-895 million versus expected $955.1 million. The company faces margin pressure from increased sales of lower-margin weight-loss drugs and international expansion. However, the upcoming launch of its Peptides+ category at month-end could provide significant growth opportunities, making the stock potentially attractive for long-term investors despite current headwinds.
- Read Full Article
Hims & Hers Q3 Earnings Miss Estimates, Gross Margin Down
Hims & Hers (HIMS) reported Q3 2026 EPS of 3 cents, missing estimates by 57.1%, though revenues grew 48.7% year-over-year to $890.4 million. The company faced margin compression due to lower-margin weight loss products and a sequential subscriber decline of 100,000. HIMS lowered its full-year adjusted EBITDA guidance to $257-$277 million but raised international revenue outlook to at least $650 million.
- Read Full Article
A $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry Shift
The global telehealth market is experiencing significant growth, projected to expand from $77.4 billion in 2025 to $187.5 billion by 2033. Key developments include AI-powered diagnostics, remote patient monitoring, and virtual care expansion. Rocket Doctor AI joined the Altais network to expand telehealth services in California, while competitors like Teladoc Health, Amwell, Hims & Hers, and Doximity launched new AI capabilities and research initiatives to enhance digital healthcare delivery.
Ways to Trade HIMS at MEXC
How to Buy Hims & Hers Health, Inc. (HIMS) Stock on MEXC
Eligible investors can buy real shares of Hims & Hers Health, Inc. (HIMS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Hims & Hers Health, Inc. (HIMS) stock price today?
2.Is HIMS stock going up or down today?
3.What is HIMS pre-market price?
4.What is HIMS after-hours price?
5.Is HIMS stock trading now?
6.Where does HIMS sit relative to its 52-week high and low?
7.What sector is Hims & Hers Health, Inc. in?
8.What is Hims & Hers Health, Inc.'s market capitalization and where is it listed?
9.How is HIMS valued in terms of P/E ratio and EPS?
10.Does Hims & Hers Health, Inc. pay a dividend?
Explore More US Stocks
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HIMS, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
HIMS Stock Calculator
Estimate the value between HIMS shares and USD.
HIMS Shares to USD
1.00 HIMS shares = 17.056 USD
Calculations are estimates based on the latest available price and are for reference only.


